Phenoxymethylpenicillin

Table of contents

• What is phenoxymethylpenicillin?
• How does phenoxymethylpenicillin work?
• Which conditions is it used or studied for?
• How is phenoxymethylpenicillin given?
• What do the clinical trials show?
• What side effects are known?

What is phenoxymethylpenicillin?

Phenoxymethylpenicillin, also known as penicillin V, is a chemically synthesised antibiotic belonging to the penicillin class. It is a narrow-spectrum antibiotic, meaning it acts against a limited range of bacteria rather than a broad range. In the Scandinavian countries, narrow-spectrum phenoxymethylpenicillin is the antibiotic of choice for respiratory tract infections, while broader spectrum amoxicillin is used in most other European countries.^[5]

The substance is already authorised as a medicine and is listed in the formulary of the Northern Care Alliance NHS Foundation Trust as tablets and an oral solution.^[4] In the CTIS registry records, phenoxymethylpenicillin appears as a comparator in two trials, meaning it serves as the comparison treatment against which newer or alternative approaches are tested.^[1]

How does phenoxymethylpenicillin work?

Phenoxymethylpenicillin is a beta-lactam antibiotic. Like other penicillins, it works by interfering with the formation of the bacterial cell wall, which bacteria need to survive and multiply. Because it is a narrow-spectrum antibiotic, it targets certain Gram-positive bacteria, including streptococci, while leaving many other bacteria unaffected. This narrow spectrum is one reason it is preferred in some settings: it treats the intended infection while reducing the impact on the body's normal bacterial flora compared with broader-spectrum antibiotics.^[5]

Which conditions is it used or studied for?

Phenoxymethylpenicillin is used in ambulatory care for infections, particularly respiratory tract infections in Scandinavian practice.^[5] In the three registered trials, it appears as a comparator in the following conditions:

• Recurrent erysipelas of the lower legs — a recurring bacterial skin infection, typically caused by streptococci, that affects the lower limbs. The trial compares compression therapy alone against compression therapy plus antibiotics, with phenoxymethylpenicillin as part of the antibiotic arm.^[1]
• Infective endocarditis caused by Gram-positive cocci — an infection of the inner lining of the heart chambers and valves caused by bacteria such as staphylococci, enterococci, and streptococci. Phenoxymethylpenicillin is one of many standard antibiotic options in the comparator arm.^[2]
• Bone and joint infections — specifically pyogenic vertebral osteomyelitis, an infection of the bones of the spine. The trial compares an early switch from intravenous to oral antibiotics after 7 days against a switch after 14 days, with phenoxymethylpenicillin among the oral options.^[3]

How is phenoxymethylpenicillin given?

Phenoxymethylpenicillin is given by mouth. The CTIS registry records list the route of administration as oral use.^[1] The NHS formulary lists two pharmaceutical forms: tablets and an oral solution.^[4] In the trials, the oral doses reported in the intervention arms include 2,000,000 international units (IU) in the erysipelas trial, 6,000,000 IU in the endocarditis trial, and 8 million IU in the vertebral osteomyelitis trial.^[1][2][3]

What do the clinical trials show?

Phenoxymethylpenicillin appears in three Phase 3 clinical trials, all currently authorised but not yet reporting results. In all three, it is part of the comparator or standard-therapy arm rather than the experimental treatment.^[1][2][3]

What are the trials measuring?

The erysipelas trial measures the proportion of patients with at least one recurrence of erysipelas during the 1-year prophylaxis phase, assessed by a blinded assessor.^[1] The endocarditis trial uses the Desirability of Outcome Ranking (DOOR) on Day 90, which ranks patients from alive with no events to death within 90 days, with events including cardiac surgery, infectious complications, and embolic events.^[2] The vertebral osteomyelitis trial measures a composite clinical failure endpoint assessed 24 weeks after stopping antibiotic therapy, including all-cause mortality, unplanned spine-related surgery, relapse of bacteraemia, relapse of the initial pathogen, and renewed intravenous antibiotic therapy for more than 7 days.^[3]

Who can take part in these trials?

The erysipelas trial enrols 200 participants with recurrent erysipelas in the lower limbs.^[1] The endocarditis trial enrols 166 participants with infective endocarditis caused by Gram-positive cocci.^[2] The vertebral osteomyelitis trial enrols 280 participants with pyogenic vertebral osteomyelitis.^[3] All three trials are interventional and randomised, and all are currently in the authorised status, meaning they are approved to proceed but have not yet published results.

What side effects are known?

The supplementary sources provided do not contain information on side effects of phenoxymethylpenicillin. The systematic review focuses on clinical effect compared with amoxicillin and does not report adverse event data in the excerpt provided.^[5]